|
Balance Sheet Cash Flow Statement 25 Minneakoning Rd. Flemington, NJ 08822 NJ Tel. 908-782-3431 Fax 908-782-2445 |
Type: Public
On the web:
http://www.novadel.com
Employees:
10
Employee growth: (28.6%)
NovaDel Pharma is developing new ways to deliver popular over-the-counter and prescription drugs...just make sure you don't grab your cologne by mistake. The company's proprietary oral spray delivery system allows for faster absorption into the bloodstream, in turn producing therapeutic benefits more quickly. NovaDel won FDA approval of its first product, NitroMist (an oral spray formulation of a common angina treatment), in 2006; the company is looking for a partner to market the drug. The company received FDA approval of its ZolpiMist, a spray version of Sanofi-Aventis' insomnia drug Ambien, in 2008. It is also developing spray versions of treatments for nausea, migraine, and central nervous system disorders.
Key numbers for fiscal year ending December, 2008:
Sales: $0.4M
One year growth: (23.0%)
Net income: ($9.6)M
Officers:
Chairman, Interim President, and Interim CEO: Steven B. Ratoff
SVP and COO: David H. Bergstrom
Interim CFO and Corporate Secretary: Deni M. Zodda
Competitors:
Bayer HealthCare
Generex Biotechnology
Sciele Pharma
